Drug Profile
Creatine monohydrate
Alternative Names: AL-02; AL-05; ALS-02; ALS-05; ALS-08/celecoxib; ALS-08/minocycline; CMT-02; CTD-02; CTD-09; DMD-02; HD-02; NEOtine; PD-01; PD-02; PD-04; PD-06; PURE ENERGYLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Avicena Group
- Class Amino acids; Guanidines; Neuroprotectants; Small molecules
- Mechanism of Action Mitochondrial protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Huntington's disease; Metabolic disorders; Neuromuscular disorders; Parkinson's disease
Most Recent Events
- 03 Jun 2010 No development reported - Phase-I for Neuromuscular disorders in USA (PO)
- 03 Jun 2010 No development reported - Phase-II for Huntington's disease in USA (PO)
- 03 Jun 2010 No development reported - Phase-III for Amyotrophic lateral sclerosis in USA (PO)